CSL (CMXHF) PEG Ratio : 4.72 (As of May. 04, 2024)

View and export this data going back to 2009. Start your Free Trial

What is CSL PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, CSL's PE Ratio without NRI is 35.37. CSL's 5-Year EBITDA growth rate is 7.50%. Therefore, CSL's PEG Ratio for today is 4.72.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

The historical rank and industry rank for CSL's PEG Ratio or its related term are showing as below:

CMXHF' s PEG Ratio Range Over the Past 10 Years
Min: 1.46 Med: 2.75 Max: 6.01
Current: 4.72

During the past 13 years, CSL's highest PEG Ratio was 6.01. The lowest was 1.46. And the median was 2.75.

CMXHF's PEG Ratio is ranked worse than
78.9% of 109 companies
in the Biotechnology industry
Industry Median: 1.58 vs CMXHF: 4.72

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

CSL PEG Ratio Historical Data

The historical data trend for CSL's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL PEG Ratio Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

PEG Ratio

Get a 7-Day Free Trial

2.18

2.77

2.63

3.22

5.46

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
PEG Ratio	Get a 7-Day Free Trial															-	3.22	-	5.46	-

Competitive Comparison of CSL's PEG Ratio

For the Biotechnology subindustry, CSL's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's PEG Ratio distribution charts can be found below:

* The bar in red indicates where CSL's PEG Ratio falls into.

CSL PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

CSL's PEG Ratio for today is calculated as

PEG Ratio	=	PE Ratio without NRI	/	5-Year EBITDA Growth Rate*
	=	35.373280943026	/	7.50
	=	4.72

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

CSL (OTCPK:CMXHF) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

CSL PEG Ratio Related Terms

Thank you for viewing the detailed overview of CSL's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CMXHF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » PEG Ratio

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.